Login

Lightstone acquires pair of New England-area life science campuses in separate deals

Newmark's Boston Capital Markets Group arranges biotech property sales in Smithfield, Rhode Island, and Burlington, Massachusetts, to private real estate investment firm
This 122,507-square-foot cGMP biomanufacturing facility at 100 Technology Way in Smithfield, Rhode Island, one of two Boston-area biotech properties acquired by Lightstone, is fully leased to Organogenesis. (CoStar)
This 122,507-square-foot cGMP biomanufacturing facility at 100 Technology Way in Smithfield, Rhode Island, one of two Boston-area biotech properties acquired by Lightstone, is fully leased to Organogenesis. (CoStar)
By Jack Quinn with
CoStar Research
April 9, 2026 | 4:58 P.M.

Lightstone Group, a large privately held real estate company founded by David Lichtenstein, with more than $12 billion in assets under management and a portfolio that includes industrial, residential, hospitality and commercial properties across 28 states, acquired a pair of life science campuses in the greater New England region.

This news story is available exclusively to CoStar subscribers.

Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.

This news story is available exclusively to CoStar subscribers.

Ready to Learn More?

Sign Up For a Personalized Demo.

Sign Up For a Demo To Learn More.

Already A Subscriber? Sign In

IN THIS ARTICLE